Prestige Consumer Healthcare

Background

Company Name	Prestige Consumer Healthcare
Stock Symbol	PBH

Submit Your Information

If you suffered a loss on your Prestige Consumer Healthcare investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filling out this form mean you have joined any lawsuit.

First Name*

Middle Initial

Last Name*

Email*

Phone*

If representing a Corporation, Trust, Partnership or other entity, Name of Entity

If representing an Entity, Position at Entity

Mailing Address

City

State/Province

ZIP/Postal Code

Country

Are you a current or former employee of the company?

Did you purchase any shares before January 01, 1970?

Shares Purchased

Number of Shares	Buy Date	Price Per Share	Add
Purchased quantity	Purchased month Purchased day Purchased year

Shares Sold

Number of Shares	Sell Date	Price Per Share	Add
	Sold month Sold day Sold year

Additional Comments

Background

On May 13, 2026, Prestige Consumer announced fourth quarter and full year 2026 earnings, including that, "for fiscal '26, revenues decreased 4.5% organically versus the prior year" and "[t]otal company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year."

In the associated earnings call, the Company’s CEO Ron Lombardi revealed "in Q4, Clear Eyes sales were below expectations due to delayed shipments and production shutdowns ahead of line updates."

On this news, shares of Prestige Consumer fell $5.88 per share, or 11.35%, to close at $45.93 on May 14, 2026.

Submit Your Information